Post-COVID SyndromeEXILENCT05445830
Exercise Intolerance in Post-COVID Patients
A study testing High-Intensity-Interval-Exercise, Moderate-Intensity-Continuous-Exercise and Strength training in people with Post-COVID Syndrome, run by Karolinska Institutet at 1 site in Sweden.
Trial summary
The post-COVID syndrome poses an unprecedented challenge to modern society, affecting millions of people worldwide. Persistent fatigue and exercise intolerance are among the most common complaints of these subjects. Read more about this study
- Who is it for?
- Ages 18 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Post-COVID Syndrome
- What is being tested?
- High-Intensity-Interval-Exercise, Moderate-Intensity-Continuous-Exercise and Strength training
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 62 participants
- Where
- 1 siteSweden
- Study dates
- 1 Sep 2022to 31 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Verified test of covid-19 infection (PCR, or antigen or antibody before vaccination) (mandatory only for post-COVID group)
- Symptoms persisting for at least 3 months (validaded with DSQ-PEM questionnarie) (only for post-COVID group)
Who cannot join
- Subject's complaints may have been present before March 2020
- Previous history cardiovascular, respiratory disease or other autoimmune disease
- History of general anxiety syndrome or somatic symptom disorder
Trial locations and contacts
1 site in 1 country.
Sweden1 site
Karolinska University Hospital Huddinge
Stockholm, Huddinge, 141 57
About this study
Official title: Physiological Characterization of Functional Limitations and Exercise Intolerance in Post-COVID Patients
The post-COVID syndrome poses an unprecedented challenge to modern society, affecting millions of people worldwide. Persistent fatigue and exercise intolerance are among the most common complaints of these subjects. The mechanisms of exercise intolerance in post-COVID subjects are remained yet unknown, which make the rehabilitation efforts complex and challenging. The overall goals of this project are to: 1) improve physiological understanding of symptoms in this clinical condition, 2) elucidate plausible mechanisms to explain exercise intolerance/symptom exacerbation, and finally 3) provide knowledge that can be directly applied in the clinical setting to improve diagnosis, care, and individualized rehabilitation of subjects with post-COVID syndrome. Post-COVID subjects and age/sex matched healthy controls will undertake a comprehensive set of physiological and functional assessments, followed by 3 experimental visits (in a randomized order), where acute exercise responses will be assessed in either continuous moderate intensity aerobic exercise, high intensity interval exercise, or strength training. The same set of physiological assessments will also be performed after 1 year in both post-COVID subjects and healthy-matched controls to better understand the time course of the syndrome. It is hypothesized that the mechanism responsible for exercise intolerance is linked to specific symptoms and will vary across subjects. However, it is expected that most post-COVID subjects will respond well to at least one type of exercise.
- Conditions
- Post-COVID Syndrome
- Being tested
- High-Intensity-Interval-Exercise, Moderate-Intensity-Continuous-Exercise, Strength training, Baseline assessment, 1 year follow-up
- Keywords
- Exercise intolerance, Acute exercise, Skeletal muscle, Cardiorespiratory fitness, Post-COVID syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High-Intensity-Interval-ExerciseProcedure or surgery
Also called HIIE
Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
Moderate-Intensity-Continuous-ExerciseProcedure or surgery
Also called MICE
Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
Strength trainingProcedure or surgery
Also called Resistance training
Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
Baseline assessmentProcedure or surgery
Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
1 year follow-upProcedure or surgery
Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
| Study group | Role | What they receive |
|---|---|---|
| Post-covid patients | Experimental | Not described Receives: Procedure: High-Intensity-Interval-Exercise; Procedure: Moderate-Intensity-Continuous-Exercise; Procedure: Strength training; Procedure: Baseline assessment; Procedure: 1 year follow-up |
| Control | Experimental | Not described Receives: Procedure: High-Intensity-Interval-Exercise; Procedure: Moderate-Intensity-Continuous-Exercise; Procedure: Strength training; Procedure: Baseline assessment; Procedure: 1 year follow-up |
What is being measured
The primary outcome is the main question the study is designed to answer.
Post-exertional malaise (PEM) symptoms of post-COVID subjects and age/sex matched controls in response to different exercise trials.
Visual analog scale (VAS) 0-10 for 10 symptoms (fatigue, muscle pain, joint pain, memory, concentration, fever, sore throat, lymph nodes, headache, chills) will be used to assess symptoms exaggeration in response to 3 different exercise trials (high intensity interval training, moderate intensity continuous exercise and strength exercise) between the post-COVID subjects and age/sex matched controls.
0=no pain/symptom to 10=maximal pain/symptom
2 groups x 3 exercise sessions x 3 timepoints per exercise (pre, post and 48h post)
Measured: Three exercises trials & 48 hours follow-ups of each trial
Secondary outcomes (19)
Absolute immune cell count in blood samples of post-COVID subjects and age/sex matched controls in response to different exercise trials.
Absolute immune count will be assessed via BD TruCount in collected blood samples (before, immediately-, and 48h-post) in response to different exercise trials (high intensity interval training, moderate intensity continuous exercise and strength exercise) across the post-COVID subjects and age/sex matched controls. PBMCs will be analysed for distribution of B cells, NK cells, monocytes, CD4+ T cells, CD8+ T cells, with additional panels to capture plasma, effector and memory cells.
Measured: Three exercises trials & 48 hours follow-ups of each exercise trial
Exploratory metabolomic and cytokine profiling using blood samples of post-COVID subjects and age/sex matched controls in response to different exercise trials.
Metabolomic and cytokine profiling will be explored in collected blood samples (before, immediately-, and 48h-post) in response to different exercise trials (high intensity interval training, moderate intensity continuous exercise and strength exercise) across the post-COVID subjects and age/sex matched controls. Olink PEA platform and GC-MS at the Swedish Metabolomics Centre in Umea will be used and targeted analysis will include IL-6, TNF-a and IFN-g profiling.
Measured: Three exercises trials & 48 hours follow-ups of each exercise trial
Cardiac function in the post-COVID subjects and age/sex matched controls
Routine echocardiography wiil be performed to assess normal/abnormal heart structure and function in the post-COVID subjects and age/sex matched controls at baseline and 1y follow-up. A blinded observer will then quantify cardiac chamber dimensions and volumes, as well as the assessment of left ventricular systolic and diastolic function.
Measured: Baseline & 1y follow-up
Respiratory function in the post-COVID subjects and age/sex matched controls
Routine spirometry wiil be performed to assess normal/abnormal lung structure and function in the post-COVID subjects and age/sex matched controls at baseline and 1y follow-up. The spirometry variables will be the forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV% (FEV1/ VC MAX), maximum vital capacity (VC MAX), total lung capacity (TLC), and diffusing capacity of the lungs for carbon monoxide single breath corrected for Hb (DLCOc SB).
Measured: Baseline & 1y follow-up
Arterial stiffness in the post-COVID subjects and age/sex matched controls
Non-invasive measurement of arterial stiffness via arteriography (Tensiomed) will be performed in the post-COVID subjects and age/sex matched controls at baseline and 1y follow-up. Higher pulse wave velocity (PWV) reflects higher degree of arterial stifness.
Measured: Baseline & 1y follow-up
Dysautonomia in the post-COVID subjects and age/sex matched controls
Head-up TILT test (HUTT) will be performed according to clinical guidelines to assess normal or abnormal autonomic nervous system regulation in the post-COVID subjects and age/sex matched controls at baseline and 1y follow-up. Specifically, hemodynamic measurements (systolic blood pressure, diastolic blood pressure and heart rate) will be measured non-invasively using NOVA software at supine position and at standing. Medical doctor will then classify the patients as follows:
- Normal orthostatic reaction
- Post-orthostatic tachycardia syndrome (POTS): development of symptoms with a sustained heart rate increase of ≥ 30 bpm or ≥ 120 bpm within 10 minutes of standing, with no significant blood pressure difference, i.e., SBP decreased by ≥ 20mmHg and DBP ≥ 10mmHg
- Syncope: significant fall of HR or BP with loss of consciousness or inability to maintain posture
- Orthostatic hypotension: any HR increase with SBP decrease of ≥ 20mmHG or DBP decrease of ≥ 10mmHG
Measured: Baseline & 1y follow-up
6-min walk test the post-COVID subjects and age/sex matched controls
The standard 6-min walk test will be performed to assess the physical function, including aerobic capacity in the post-COVID subjects and age/sex matched controls at baseline and 1y follow-up. Higher distance (in meters) covered by the participants reflects better physical function and aerobic capacity.
Measured: Baseline & 1y follow-up
Handgrip strength the post-COVID subjects and age/sex matched controls
The gold standard Jama hydraulic hand dynamometer will be used to measure handgrip strength of the domiant hand to assess upper body muscular strength in the post-COVID subjects and age/sex matched controls at baseline and 1y follow-up.
Measured: Baseline & 1y follow-up
Blood volume in the post-COVID subjects and age/sex matched controls
The optimized carbon monoxide rebreathing method will be used to determine total hemoglobin, from which blood volume and plasma volume will later calculate using hemoglobin concentration [Hb] and hematocrit (Hct). This method will be conducted in the post-COVID subjects and age/sex matched controls at baseline and 1y follow-up.
Measured: Baseline & 1y follow-up
Lower body muscle strength the post-COVID subjects and age/sex matched controls
Maximal isometric (120°/s) and isokinetic strength (60°/s and 210°/s) will be measured using Biodex isokinetic dynamometer to assess lower body muscular strength in the post-COVID subjects and age/sex matched controls at baseline and 1y follow-up.
Measured: Baseline & 1y follow-up
Nerve conduction studies the post-COVID subjects and age/sex matched controls
Nerve conductions studies (NCS) will be conducted in the dominant lower and upper limb using the Cadwell Sierra Summit EMG system (Cadwell Industries, Inc., Kennewick, WA). Motor studies included the median, ulnar, fibular, and tibial nerves, and the compound muscle action potential (CMAP), distal latency (DL), conduction velocity (CV), and minimum F-wave latency will be recorded for all nerves. Sensory studies will include median, ulnar, radial, sural, and fibular nerves, and the sensory nerve action potential (SNAP) and CV will be recorded for all nerves. NCS will be performed in the post-COVID patients and age/sex matched controls at baseline and 1y follow-up
Measured: Baseline & 1y follow-up
Needle Electromyography in the post-COVID subjects and age/sex matched controls
Needle electromyography (EMG) of 6 muscles (deltoid, biceps brachii, trapezius, anterior tibial, vastus medialis, and adductor magnus) will be performed using Sierra Summit EMG system in all participants at baseline and 1y follow-up. Multi-MUP analysis and routine EMG will be performed to record and assess MUPs qualitative and semi-quantitatively. Mean duration (simple MUPs), amplitude, and percentage of polyphasic MUPs will be recorded.
Measured: Baseline & 1y follow-up
Sympathetic skin response in the post-COVID subjects and age/sex matched controls
Sympathetic skin response (SSR) will be conducted to the dominant palm and sole using Sierra Summit EMG system to assess autonomic sympathetic function. The response will be recorded, and the latency determined from the onset of the stimulus artifact to first deflection from baseline. A response will be defined as absent if no reproducible deflection is recorded after consecutive and sporadic stimulations. This test will be performed in post-COVID subjects and age/sex matched controls at baseline and 1y follow-up.
Measured: Baseline & 1y follow-up
Heart rate variability in the post-COVID subjects and age/sex matched controls
Heart rate variability (HRV) using continuous electrocardiogram (ECG) will be recorded by a two-lead electrocardiograph using the Sierra Summit EMG system. The variation in R-R interval during normal breathing and during deep breathing will be recorded and the variability calculated as maximum heart rate minus minimum heart rate divided by average heart rate, expressed as a percentage. This test will be performed in post-COVID subjects and age/sex matched controls at baseline and 1y follow-up.
Measured: Baseline & 1y follow-up
Muscle biopsy in the post-COVID subjects and age/sex matched controls
Tissue samples of the vastus lateralis muscle will be obtained under local anaesthesia using the percutaneous Bergström technique from the right leg. All muscle samples (~200 mg) will be immediately dissected free of any visible fat, excess blood and connective tissue, and then quickly frozen in liquid nitrogen. Samples were stored at -80°C until the analyses. Muscle biopsies will be collected in post-COVID subjects and age/sex matched controls at baseline and 1y follow-up.
Measured: Baseline & 1y follow-up
Exercise (in)capacity of post-COVID subjects and age/sex matched controls
Cardiopulmonary exercise testing (CPET) will be used to assess exercise capacity as the peak volume of oxygen consumption (VO2 peak) in all participants at several timepoints in this study. First at baseline, then 48h after each exercise trial and finally at the 1y follow-up.
Measured: Baseline & 48 hours follow-ups of each trial & 1y follow-up
Post-exertional symptoms using the Multifactional Fatigue Inventory (MFI) in post-COVID subjects and age/sex matched controls in response to different exercise trials.
Multifactional Fatigue Inventory (MFI) validated questionnarie will be administrated to assess fatigue exaggeration in response to 3 different exercise trials (high intensity interval training, moderate intensity continuous exercise and strength exercise) between the post-COVID subjects and age/sex matched controls. MFI is a 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Higher scores reflect higher fatigue levels.
2 groups x 3 exercise sessions x 3 timepoints per exercise (pre, post and 48h post)
Measured: Three exercises trials & 48 hours follow-ups of each trial
Post-exertional symptoms using the Profile of Mood States (POMS) in post-COVID subjects and age/sex matched controls in response to different exercise trials.
Profile of Mood States (POMS) instrument will be administrated to assess different dimensions of mood states in response to 3 different exercise trials (high intensity interval training, moderate intensity continuous exercise and strength exercise) between the post-COVID subjects and age/sex matched controls. POMS measures six different dimensions of mood swings over a period of time. These include: Tension or Anxiety, Anger or Hostility, Vigor or Activity, Fatigue or Inertia, Depression or Dejection, Confusion or Bewilderment.
Higher scores reflect increased levels mood states (i.e. higher tension level).
2 groups x 3 exercise sessions x 3 timepoints per exercise (pre, post and 48h post)
Measured: Three exercises trials & 48 hours follow-ups of each trial
Post-exertional symptoms using the Somatic and Psychological Health REport (SPHERE) instrument in post-COVID subjects and age/sex matched controls in response to different exercise trials.
The Somatic and Psychological HEalth REport (SPHERE) is a 34-item self-report questionnaire that assesses symptoms of mental distress and persistent fatigue. Scores from 12 selected questions will be used to calculate the subscale of SOMA reflect physical fatigue (6 questions) and PHYCH metnal distress (6 questions) respectively. SPHERE instrument will be administrated to assess mental stress and persisent fatigue in response to 3 different exercise trials (high intensity interval training, moderate intensity continuous exercise and strength exercise) between the post-COVID subjects and age/sex matched controls.
Higher SOMA and PHYCH scores reflect increased levels persistent physical fatigue and mental stress respectively.
2 groups x 3 exercise sessions x 2 timepoints per exercise (pre and 48h post)
Measured: Three exercises trials & 48 hours follow-ups of each trial
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2022
- Study start1 Sep 2022
- Primary completion15 Sep 2023
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Post-COVID SyndromeStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 62 participants (actual)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- Karolinska University Hospital
- Responsible party
- Principal investigator, Tommy Lundberg, Karolinska Institutet
- Investigators
- Thomas Gustafsson, Prof, Study chair, Karolinska Institutet and Karolinska University HospitalHelene Rundqvist, PhD, Principal investigator, Karolinska InstitutetTommy Lundberg, PhD, Principal investigator, Karolinska InstitutetKaveh Pourhamidi, PhD, Study chair, Karolinska University HospitalAndrea Tryfonos, PhD, Study director, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05445830
- Sponsor's protocol ID
- 2021-05758-01
- Acronym
- EXILE
- Status last verified
- Aug 2026
- First submitted
- 2 Jul 2022
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be anonymised and available in public database and/or as supplementary data in peer reviewed publications following the completion of the study.
Publications
Tryfonos A, Jornaker G, Rundqvist H, Pourhamidi K, Melin M, Wallin H, Larsen FJ, Pantelios S, Mutvei AP, Tillander V, Tietge UJF, Diaz SP, Crafoord D, Lovric A, Fernandez-Gonzalo R, Rullman E, Stal P, Gustafsson T, Rundqvist H, Lundberg TR. Muscle Abnormalities in Nonhospitalised Patients With Post-COVID-19 Condition. J Cachexia Sarcopenia Muscle. 2025 Oct;16(5):e70085. doi: 10.1002/jcsm.70085.
PubMed 41030235Tryfonos A, Pourhamidi K, Jornaker G, Engvall M, Eriksson L, Elhallos S, Asplund N, Mandic M, Sundblad P, Sepic A, Rullman E, Hyllienmark L, Rundqvist H, Lundberg TR, Gustafsson T. Functional Limitations and Exercise Intolerance in Patients With Post-COVID Condition: A Randomized Crossover Clinical Trial. JAMA Netw Open. 2024 Apr 1;7(4):e244386. doi: 10.1001/jamanetworkopen.2024.4386.
PubMed 38573638
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Physiological Characterization of Functional Limitations and Exercise Intolerance in Post-COVID Patients
- ClinicalTrials.gov ID
- NCT05445830
- Acronym / sponsor ID
- EXILE / 2021-05758-01
- Conditions
- Post-COVID Syndrome
- Keywords
- Exercise intolerance, Acute exercise, Skeletal muscle, Cardiorespiratory fitness, Post-COVID syndrome
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 62 participants (actual)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Collaborators
- Karolinska University Hospital
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 15 Sep 2023 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 6 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The post-COVID syndrome poses an unprecedented challenge to modern society, affecting millions of people worldwide. Persistent fatigue and exercise intolerance are among the most common complaints of these subjects. The mechanisms of exercise intolerance in post-COVID subjects are remained yet unknown, which make the rehabilitation efforts complex and challenging. The overall goals of this project are to: 1) improve physiological understanding of symptoms in this clinical condition, 2) elucidate plausible mechanisms to explain exercise intolerance/symptom exacerbation, and finally 3) provide knowledge that can be directly applied in the clinical setting to improve diagnosis, care, and individualized rehabilitation of subjects with post-COVID syndrome. Post-COVID subjects and age/sex matched healthy controls will undertake a comprehensive set of physiological and functional assessments, followed by 3 experimental visits (in a randomized order), where acute exercise responses will be assessed in either continuous moderate intensity aerobic exercise, high intensity interval exercise, or strength training. The same set of physiological assessments will also be performed after 1 year in both post-COVID subjects and healthy-matched controls to better understand the time course of the syndrome. It is hypothesized that the mechanism responsible for exercise intolerance is linked to specific symptoms and will vary across subjects. However, it is expected that most post-COVID subjects will respond well to at least one type of exercise.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Post-covid patients | Experimental | Procedure: High-Intensity-Interval-Exercise, Procedure: Moderate-Intensity-Continuous-Exercise, Procedure: Strength training, Procedure: Baseline assessment, Procedure: 1 year follow-up |
| Control | Experimental | Procedure: High-Intensity-Interval-Exercise, Procedure: Moderate-Intensity-Continuous-Exercise, Procedure: Strength training, Procedure: Baseline assessment, Procedure: 1 year follow-up |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Verified test of covid-19 infection (PCR, or antigen or antibody before vaccination) (mandatory only for post-COVID group)
- Symptoms persisting for at least 3 months (validaded with DSQ-PEM questionnarie) (only for post-COVID group)
Key exclusion criteria (3 listed)
- Subject's complaints may have been present before March 2020
- Previous history cardiovascular, respiratory disease or other autoimmune disease
- History of general anxiety syndrome or somatic symptom disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High-Intensity-Interval-ExerciseAlso: HIIESubjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling. | Procedure or surgery | Control, Post-covid patients |
| Moderate-Intensity-Continuous-ExerciseAlso: MICESubjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling. | Procedure or surgery | Control, Post-covid patients |
| Strength trainingAlso: Resistance trainingSubjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling. | Procedure or surgery | Control, Post-covid patients |
| Baseline assessmentSubjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy. | Procedure or surgery | Control, Post-covid patients |
| 1 year follow-upSubjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy. | Procedure or surgery | Control, Post-covid patients |
Primary outcome
Post-exertional malaise (PEM) symptoms of post-COVID subjects and age/sex matched controls in response to different exercise trials.
Time frame: Three exercises trials & 48 hours follow-ups of each trial
Visual analog scale (VAS) 0-10 for 10 symptoms (fatigue, muscle pain, joint pain, memory, concentration, fever, sore throat, lymph nodes, headache, chills) will be used to assess symptoms exaggeration in response to 3 different exercise trials (high intensity interval training, moderate intensity continuous exercise and strength exercise) between the post-COVID subjects and age/sex matched controls. 0=no pain/symptom to 10=maximal pain/symptom 2 groups x 3 exercise sessions x 3 timepoints per exercise (pre, post and 48h post)
19 secondary outcomes
Absolute immune cell count in blood samples of post-COVID subjects and age/sex matched controls in response to different exercise trials.
Time frame: Three exercises trials & 48 hours follow-ups of each exercise trial
Exploratory metabolomic and cytokine profiling using blood samples of post-COVID subjects and age/sex matched controls in response to different exercise trials.
Time frame: Three exercises trials & 48 hours follow-ups of each exercise trial
Cardiac function in the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Respiratory function in the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Arterial stiffness in the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Dysautonomia in the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
6-min walk test the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Handgrip strength the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Blood volume in the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Lower body muscle strength the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Nerve conduction studies the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Needle Electromyography in the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Sympathetic skin response in the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Heart rate variability in the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Muscle biopsy in the post-COVID subjects and age/sex matched controls
Time frame: Baseline & 1y follow-up
Exercise (in)capacity of post-COVID subjects and age/sex matched controls
Time frame: Baseline & 48 hours follow-ups of each trial & 1y follow-up
Post-exertional symptoms using the Multifactional Fatigue Inventory (MFI) in post-COVID subjects and age/sex matched controls in response to different exercise trials.
Time frame: Three exercises trials & 48 hours follow-ups of each trial
Post-exertional symptoms using the Profile of Mood States (POMS) in post-COVID subjects and age/sex matched controls in response to different exercise trials.
Time frame: Three exercises trials & 48 hours follow-ups of each trial
Post-exertional symptoms using the Somatic and Psychological Health REport (SPHERE) instrument in post-COVID subjects and age/sex matched controls in response to different exercise trials.
Time frame: Three exercises trials & 48 hours follow-ups of each trial
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
- Derived from this study: PubMed 41030235Tryfonos A, Jornaker G, Rundqvist H, Pourhamidi K, Melin M, Wallin H, Larsen FJ, Pantelios S, Mutvei AP, Tillander V, Tietge UJF, Diaz SP, Crafoord D, Lovric A, Fernandez-Gonzalo R, Rullman E, Stal P, Gustafsson T, Rundqvist H, Lundberg TR. Muscle Abnormalities in Nonhospitalised Patients With Post-COVID-19 Condition. J Cachexia Sarcopenia Muscle. 2025 Oct;16(5):e70085. doi: 10.1002/jcsm.70085.
- Derived from this study: PubMed 38573638Tryfonos A, Pourhamidi K, Jornaker G, Engvall M, Eriksson L, Elhallos S, Asplund N, Mandic M, Sundblad P, Sepic A, Rullman E, Hyllienmark L, Rundqvist H, Lundberg TR, Gustafsson T. Functional Limitations and Exercise Intolerance in Patients With Post-COVID Condition: A Randomized Crossover Clinical Trial. JAMA Netw Open. 2024 Apr 1;7(4):e244386. doi: 10.1001/jamanetworkopen.2024.4386.
- Individual participant dataSharing planned: Yes. Data will be anonymised and available in public database and/or as supplementary data in peer reviewed publications following the completion of the study.
Related trials for Post-COVID Syndrome
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
RecruitingPhase 2
DAOIB for the Treatment of Brain Fog
Long COVID
Active, not recruitingObservational study
Pain in Long COVID-19: The Role of Sleep
Long COVID
Recruiting
Effect of Hi-OxSR for the Treatment of Post COVID Condition
Long COVID, Post COVID-19 Condition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Gustafsson, Prof study chair
Karolinska Institutet and Karolinska University Hospital
Helene Rundqvist, PhD principal investigator
Karolinska Institutet
Tommy Lundberg, PhD principal investigator
Karolinska Institutet
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High-Intensity-Interval-Exercise, Moderate-Intensity-Continuous-Exercise and Strength training in people with Post-COVID Syndrome, run by Karolinska Institutet at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Post-exertional malaise (PEM) symptoms of post-COVID subjects and age/sex matched controls in response to different exercise trials. (time frame: Three exercises trials & 48 hours follow-ups of each trial). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05445830, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.